Orion Oyj (OTCMKTS:ORINY - Get Free Report)'s stock price rose 2% during trading on Wednesday . The stock traded as high as $26.63 and last traded at $26.63. Approximately 155 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 5,747 shares. The stock had previously closed at $26.10.
Orion Oyj Stock Performance
The stock's fifty day moving average price is $23.89 and its two-hundred day moving average price is $24.66. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.41 and a current ratio of 2.42. The company has a market cap of $7.44 billion, a P/E ratio of 20.99 and a beta of 0.25.
About Orion Oyj
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
Read More
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
